LENZ Therapeutics, Inc.
- LENZ
- NASDAQ
- Biotechnology
- Ophthalmology/Vision Care
- Clinical-Stage Biopharma
$3.27
Today −8.40%Quote Oct 16, 2026, 08:00 PM UTC
−20.82%over the last month
Max drawdown −20.8%From 1-month high −20.8%3 months −34.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$102.7M
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$7.00
+114.1% from here
Floor
$3.12
4.5% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LENZPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $5.5M
- License$3.8M68.4%
- Product$1.7M31.6%
Industry
Biotechnology
Employees
152